Drug Profile


Alternative Names: EMD-387008

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer Poxel
  • Class Amines; Antihyperglycaemics; Small molecules; Triazines
  • Mechanism of Action AMP activated protein kinase stimulants; Glucose modulators; Mitochondrial permeability transition pore inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 30 Oct 2017 Sumitomo Dainippon Pharma and Poxel agree to promote and develop imeglimin in Japan, China, South Korea, Taiwan and nine other South east Asian countries for Type 2 diabetes
  • 14 Sep 2017 Adverse events and efficacy data from a phase IIb trial in Type-2 diabetes mellitus presented at the 53rd annual meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 28 Aug 2017 Preclinical data in Type-2 diabetes mellitus presented at the Annual Congress of the European Society of Cardiology 2017 (ESC-Card-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top